Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Babich

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1991
Technetium-99m-HMPAO retention and the role of glutathione: the debate continuesJ W Babich
Nuclear Medicine and Biology|January 1, 1995
Effect of "co-ligand" on the biodistribution of 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptidesJ W Babich, A J Fischman
European Journal of Nuclear Medicine|May 1, 1997
Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cellsJ W Babich, W Graham, A J Fischman
Seminars in Nuclear Medicine|April 1, 1994
Infection imaging with technetium-99m-labeled chemotactic peptide analogsA J Fischman, J W Babich, R H Rubin
Nuclear Medicine Communications|September 1, 1989
The future of PETV R McCready, R J Ott, J W Babich
British Journal of Cancer|September 1, 1996
Evaluation of phenylpiperazines as targeting agents for neuroblastomaJ W Babich, W A Graham, A J Fischman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1993
A ticket to ride: peptide radiopharmaceuticalsA J Fischman, J W Babich, H W Strauss
Nuclear Medicine and Biology|July 1, 1995
Comparison of the infection imaging properties of a 99mTc labeled chemotactic peptide with 111In IgGJ W Babich, W Graham, S A Barrow, et al.
Progress in Clinical and Biological Research|January 1, 1991
Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastomaR J Mairs, W J Angerson, J W Babich, et al.
European Journal of Nuclear Medicine|January 1, 1987
99mTc-HMPAO as a tumour blood flow agentP A Hammersley, V R McCready, J W Babich, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1991
Technetium-99m-HMPAO retention and the role of glutathione: the debate continuesJ W Babich
Nuclear Medicine and Biology|January 1, 1995
Effect of "co-ligand" on the biodistribution of 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptidesJ W Babich, A J Fischman
European Journal of Nuclear Medicine|May 1, 1997
Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cellsJ W Babich, W Graham, A J Fischman
Seminars in Nuclear Medicine|April 1, 1994
Infection imaging with technetium-99m-labeled chemotactic peptide analogsA J Fischman, J W Babich, R H Rubin
Nuclear Medicine Communications|September 1, 1989
The future of PETV R McCready, R J Ott, J W Babich
British Journal of Cancer|September 1, 1996
Evaluation of phenylpiperazines as targeting agents for neuroblastomaJ W Babich, W A Graham, A J Fischman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1993
A ticket to ride: peptide radiopharmaceuticalsA J Fischman, J W Babich, H W Strauss
Nuclear Medicine and Biology|July 1, 1995
Comparison of the infection imaging properties of a 99mTc labeled chemotactic peptide with 111In IgGJ W Babich, W Graham, S A Barrow, et al.
Progress in Clinical and Biological Research|January 1, 1991
Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastomaR J Mairs, W J Angerson, J W Babich, et al.
European Journal of Nuclear Medicine|January 1, 1987
99mTc-HMPAO as a tumour blood flow agentP A Hammersley, V R McCready, J W Babich, et al.
Pageof 7